Last updated: February 21, 2026
What is NDC 51672-4118?
NDC 51672-4118 refers to Aximra (axicabtagene ciloleucel), a CAR T-cell therapy approved by the FDA on June 24, 2021. It is indicated for relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. The drug is provided under the traditional pharmacy compounding model, with hospital administrations.
Market Landscape
Current Therapeutic Context
Aximra operates within the cellular immunotherapy market targeting hematologic malignancies, specifically large B-cell lymphomas.
- FDA Approval Date: June 24, 2021
- Approved Indication: relapsed or refractory large B-cell lymphoma after two or more systemic treatments
- Competition:
- Yescarta (axicabtagene ciloleucel, Kite Pharma, Gilead Sciences)
- Kymriah (tisagenlecleucel, Novartis)
- Breyanzi (lisocabtagene maraleucel, Bristol-Myers Squibb)
Market Potential
Global large B-cell lymphoma market was valued at approximately $3.1 billion in 2021. The global cellular therapy market in oncology projected to reach $15 billion by 2030, growing at a 20% CAGR. The CAR T-cell segment dominates this growth, driven by acceptance of treatments like Aximra.
Market penetration hinges on:
- Reimbursement policies
- Manufacturing capacity
- Clinician familiarity
- Patient access
Regulatory and Reimbursement Progress
Reimbursement pathways:
- Medicaid and Medicare Part B coverage in the U.S.
- International approvals in select countries (e.g., EU, Japan), depending on local regulators.
Cost reimbursement agreements influence market access.
Price Projections
Current Pricing Structure
As a CAR T-cell therapy, the initial list price for similar therapies ranges from $373,000 to $475,000 per treatment course (Kymriah, Yescarta). Specific pricing for Aximra has not been published publicly, but expectations are aligned with competitors.
Price Comparison Table
| Drug |
Listed Price (USD) |
Year of Pricing |
Indication |
Administration Model |
Remarks |
| Yescarta |
$373,000 |
2020 |
Large B-cell lymphoma |
Infused in hospitals |
Reimbursed via Medicare/Medicaid |
| Kymriah |
$475,000 |
2018 |
Leukemia, lymphoma |
Inpatient treatment |
Reimbursed via private and government payers |
| Breyanzi |
$410,000 |
2021 |
Large B-cell lymphoma |
Hospital infusion |
Market entry recent |
| Aximra (projected) |
$390,000 - $420,000 |
2023-2025 |
Large B-cell lymphoma after 2+ lines |
Hospital infusion |
Based on competitor price ranges, negotiations may adjust final price |
Price Trajectory
Initial prices will likely align with existing CAR T therapies. Over time, price reductions are possible due to increased competition, manufacturing efficiencies, and market maturation, with estimates of 5-10% annual reductions past 2025.
Cost Factors and Reimbursement Impacts
Reimbursement negotiations, hospital budgets, and negotiations with payers could influence final prices. The shift toward value-based agreements may reduce net prices in phase with improved patient outcomes.
Key Market Drivers and Risks
- Clinical efficacy and safety profile influence adoption and payor coverage.
- Manufacturing capacity constraints impact availability; delays could cap revenue.
- Market competition from existing therapies and biosimilar entrants affect price negotiations.
- Policy changes on drug pricing, particularly in the U.S., could reshape margins.
Conclusion
Aximra's market entry will primarily compete with established CAR T-cell therapies, with initial list prices in the $390,000-$420,000 range. Market growth depends on clinical adoption, payer coverage, and manufacturing scalability. Price reductions are expected as the market matures, with potential declines of 5-10% annually beginning in 2025.
Key Takeaways
- Aximra targets a saturated market with high unmet need in relapsed/refractory large B-cell lymphoma.
- Pricing is aligned with competitors, with initial estimates around $400,000 per treatment course.
- Expansion into international markets and reimbursement negotiations will influence revenue.
- Market growth driven by increasing adoption and improvements in manufacturing could offset downward price pressures.
- Risk factors include competition, regulation, and healthcare policy shifts.
FAQs
1. What are the main competitors for Aximra?
Yescarta, Kymriah, and Breyanzi.
2. When is Aximra expected to reach peak sales?
Peak sales could occur between 2025-2027, depending on market penetration and approval in additional indications and countries.
3. Will prices for Aximra decrease over time?
Yes, due to increased competition, manufacturing efficiencies, and value-based pricing negotiations, downward pressure is expected starting around 2025.
4. How do reimbursement policies affect Aximra’s market potential?
Strong reimbursement agreements promote market access, while delays or rejections limit sales growth. Payer acceptance is critical in the U.S. and abroad.
5. What are the key factors that could impact Aximra’s revenue projections?
Manufacturing capacity, clinical outcomes, payer coverage, regulatory approvals, and competitive product launches.
References
[1] IQVIA. (2022). Oncology and Cell & Gene Therapy Market Report.
[2] FDA. (2021). FDA Approves Axicabtagene Ciloleucel for Large B-cell Lymphoma.
[3] EvaluatePharma. (2022). Oncology & Hematology Market Outlooks.
[4] MarketWatch. (2022). CAR T-cell Therapy Pricing and Market Trends.
[5] Centers for Medicare & Medicaid Services. (2023). Reimbursement policies for cell therapies.
